These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14669747)

  • 1. Plasma concentration profile of orally administered pimobendan and plasma brain natriuretic peptide level in patients with severe heart failure.
    Wakaumi M; Shiga T; Naganuma M; Matsuda N; Tatami S; Kasanuki H
    Cardiovasc Drugs Ther; 2003 May; 17(3):291-3. PubMed ID: 14669747
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
    Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract]   [Full Text] [Related]  

  • 4. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
    Butler J; Giamouzis G; Giannakoulas G
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
    Celik T; Iyisoy A; Yuksel UC; Kardesoglu E
    Int J Cardiol; 2008 Aug; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure.
    Kawano H; Arakawa S; Satoh O; Matsumoto Y; Hayano M; Nakatomi D; Yamasa T; Maemura K
    Geriatr Gerontol Int; 2014 Jan; 14(1):109-14. PubMed ID: 23581555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
    Mueller T; Gegenhuber A; Haltmayer M
    Int J Cardiol; 2005 Oct; 104(3):355-6; author reply 357-8. PubMed ID: 15950299
    [No Abstract]   [Full Text] [Related]  

  • 9. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and treatment of congestive heart failure secondary to dilated cardiomyopathy in a hedgehog.
    Delk KW; Eshar D; Garcia E; Harkin K
    J Small Anim Pract; 2014 Mar; 55(3):174-7. PubMed ID: 24372164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Hagemeijer F; Brand HJ; van Mechelen R
    Am J Cardiol; 1989 Mar; 63(9):571-6. PubMed ID: 2919561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG; Saunders AB; Roland RM; Winter RL; Drourr L; Achen SE; Hariu CD; Fries RC; Boggess MM; Miller MW
    J Am Vet Med Assoc; 2012 Jul; 241(1):89-94. PubMed ID: 22720992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levosimendan. Clinical indications of a new vasoactive substance].
    Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
    Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidural anesthesia for herniorrhaphy in a patient with severe dilated cardiomyopathy (DCM) under pimobendan control].
    Shiraishi M; Murayama K; Hanzawa K; Warabi K; Kamiyama Y
    Masui; 1997 Jan; 46(1):114-8. PubMed ID: 9028094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
    Hagemeijer F; Brand HJ; Roth W
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):302-10. PubMed ID: 2476606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic performance during exercise in patients with severe chronic congestive heart failure before and after a single dose of pimobendan.
    Hagemeijer F
    J Cardiovasc Pharmacol; 1994 May; 23(5):741-6. PubMed ID: 7521456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.